Phibro Animal Health Q1 FY2027 Earnings Call: Awaiting Details, Prior Concerns Persist

What happened

Phibro Animal Health held its Q1 FY2027 earnings call on November 5, 2026, with CEO Daniel Bendheim, CFO Glenn David, and COO Larry Miller presenting to analysts from JPMorgan and BNP Paribas. The call follows the company's Q1 FY2026 results, which showed net sales of $363.9 million and adjusted EPS of $0.65, and reiterated FY2026 guidance of $1.43–$1.48 billion sales and $230–$240 million adjusted EBITDA. However, the company's balance sheet remains strained with net debt/EBITDA at 4.72x and interest coverage of only 3.37x, while valuation appears full at 25x earnings and 19x EV/EBITDA. Regulatory risk lingers over the FDA's proposed withdrawal of carbadox (Mecadox), which accounted for about $22 million in trailing sales and could pressure earnings if banned. The market will scrutinize whether management can demonstrate margin expansion, de-leveraging, and progress on the Zoetis acquisition integration, as prior guidance relied on those factors.

Implication

Investors should look for evidence that the company is on track to meet or exceed its FY2026 adjusted EBITDA target and that leverage is trending down. A favorable FDA resolution on Mecadox would remove a key overhang and could justify a more constructive stance. Conversely, any margin erosion, guidance cut, or adverse regulatory news would likely trigger a downgrade. The current valuation leaves little room for error, so risk/reward is balanced. We would need to see at least two consecutive quarters of strong execution and de-leveraging before turning bullish.

Thesis delta

The thesis has not materially changed with the mere occurrence of the call; we need the actual results and commentary to assess any shift. Prior watch items—guidance execution, leverage reduction, and FDA outcome—remain paramount. Until we see either improved margins or a resolution of the carbadox issue, we maintain a HOLD.